Developing as a noteworthy breakthrough in the battle against obesity, the drug is attracting considerable attention . This treatment combines the action of two established GLP-1 receptor agonists, semaglutide , plus an additional glucose-dependent peptide component. Initial patient results have demonstrated significant fat reduction in individual